EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with rituximab



Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with rituximab



Onkologie 23(Sonderheft 7): 75, October




(PDF 0-2 workdays service: $29.90)

Accession: 035980687

Download citation: RISBibTeXText



Related references

Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD-20 antibody IDEC-C2B8. Neurology 56(8 Supplement 3): A411, April 24, 2001

Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncology Reports 10(6): 1915-1917, 2003

Treatment of patients with relapsed or refractory aggressive non-Hodgkins-lymphoma with rituximab and combination chemotherapy. Onkologie 23(Sonderheft 7): 154, October, 2000

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematological Oncology 31(3): 143-150, 2014

Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical Lymphoma & Myeloma 7(6): 406-412, 2007

Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study. Leukemia Research 27(12): 1097-1099, December, 2003

Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leukemia & Lymphoma 56(4): 1123-1125, 2016

Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study. Clinical Lymphoma, Myeloma & Leukemia 15(7): 398-403, 2016

Refractory, relapsed aggressive non-Hodgkins lymphoma responding to Rituximab combined with chemotherapy. Blood 94(10 SUPPL 1 PART 2): 267b, Nov 15, 1999

Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology 24(18_suppl): 7578-7578, 2016

Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. British Journal of Haematology 148(5): 810-812, 2010

Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure. Journal of the Chinese Medical Association 76(4): 195-200, 2014

A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Medical Journal 50(2): 280-283, 2009

A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology Non-Hodgkins Lymphoma. Blood 102(11): 288b, November 16, 2003